

67th ASH Annual Meeting & Exposition: Revumenib Abstracts/Presentations

Saturday, December 6th	
Oral presentation: Menin Inhibition as a New Therapeutic Option for the Myeloproliferative Neoplasms	• Session Name: 631. Myeloproliferative Syndromes & CML: Basic & Translational: Precision Targeting in MPN • Session Time: 9:30–11:00 AM • Presentation Time: 9:30–9:45 AM • Room: OCCC – W414AB • Publication Number: 67
Oral presentation: Phase II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in Newly Diagnosed AML	• Session Name: 617. AML: Commercially Available Therapies: Frontline Treatment with Intensive or Lower-intensity Regimens • Session Time: 9:30–11:00 AM • Presentation Time: 10:30–10:45 AM • Room: OCCC – Valencia Room W415A • Publication Number: 47

67th ASH Annual Meeting & Exposition: Revumenib Abstracts/Presentations

Sunday, December 7th	
Poster: Real-World Treatment Patterns and Outcomes Among Patients with Newly Diagnosed NPM1-Mutated Acute Myeloid Leukemia in the United States	• Session Name: 615. AML: Clinical & Epidemiological: Poster II • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 3385
Poster: Phase 1 Study of Revumenib in Combination With Intensive Chemotherapy (IC) in Patients (Pts) With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Harboring Genetic Alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708	• Session Name: 616. AML: Investigational Drug & Cellular Therapies: Poster II • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 3425
Poster: Revumenib for Patients with Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by Prior Treatment in the Phase 2 AUGMENT-101 Study	• Session Name: 616. AML: Investigational Drug & Cellular Therapies: Poster II • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 3418
Poster: Preliminary Results of a Phase 1 Study of the Safety and Tolerability of the Combination of Revumenib (REV) With Gilteritinib (GILT) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	• Session Name: 616. AML: Investigational Drug & Cellular Therapies: Poster II • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 3427
Poster: Early Real-world Experience with Revumenib Outside of a Clinical Trial Setting: A Single Center Retrospective Review of Efficacy and Tolerability	• Session Name: 617. AML: Commercially Available Therapies: Poster II • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 3448
Poster: Post-Transplant Maintenance with Revumenib in Children with HOX-driven AML	• Session Name: 617. AML: Commercially Available Therapies: Poster II • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 3461
Poster: Single-cell Transcriptomic Studies Reveal Altered Heterogeneity in CD41 Enriched Megakaryocytes After Targeted Therapy in Myeloproliferative Neoplasm	• Session Name: 631. Myeloproliferative Syndromes & CML: Basic & Translational: Poster II • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 3764

67th ASH Annual Meeting & Exposition: Revumenib Abstracts/Presentations

Monday, December 8th	
Oral presentation: Revumenib for Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia: Outcomes by Leukemia Type in the Phase 2 AUGMENT-101 Study	• Session Name: 617. AML: Commercially Available Therapies: Combination Regimens & Targeted Therapies • Session Time: 4:30–6:00 PM • Presentation Time: 5:30–5:45 PM • Room: OCCC – Chapin Theater (W320) • Publication Number: 1001
Poster: Co-targeting Menin and RAS in KMT2A-r/NPM1c AML with Activated RTK/RAS/ MAPK Signaling	• Session Name: 604. Molecular Pharmacology & Drug Resistance: Myeloid Neoplasms: Poster III • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 5060
Poster: Revumenib in Combination with Intensive Induction and Consolidation for Newly Diagnosed Patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary Results from the Phase 1b ETCTN 10596 Study	• Session Name: 616. AML: Investigational Drug & Cellular Therapies: Poster III • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 5206
Poster: Trial in Progress: A Multicenter Phase 1 Trial Evaluating the Safety and Preliminary Efficacy of Revumenib as Post-Transplant Maintenance After Allogeneic Hematopoietic Cell Transplant in patients with KMT2A-Rearranged or NPM1-Mutated Acute Leukemia	• Session Name: 616. AML: Investigational Drug & Cellular Therapies: Poster III • Session Time: 6:00–8:00 PM • Presentation Time: 6:00–8:00 PM • Room: OCCC – West Halls B3-B4 • Publication Number: 5207